Prestige Consumer Healthcare (NYSE:PBH) Rating Increased to Buy at Sidoti

Sidoti upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a neutral rating to a buy rating in a report released on Wednesday morning, MarketBeat.com reports. The firm currently has $80.00 target price on the stock.

A number of other equities research analysts have also commented on PBH. Wall Street Zen lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Zacks Research lowered Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Thursday, September 4th. Finally, Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $94.80.

Prestige Consumer Healthcare Stock Up 0.4%

Shares of NYSE:PBH opened at $63.26 on Wednesday. The company’s fifty day moving average is $68.34 and its 200-day moving average is $77.99. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. Prestige Consumer Healthcare has a 52 week low of $61.93 and a 52 week high of $90.04. The company has a market capitalization of $3.11 billion, a PE ratio of 14.85, a P/E/G ratio of 1.99 and a beta of 0.46.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.01 by ($0.06). The firm had revenue of $249.53 million for the quarter, compared to the consensus estimate of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The company’s revenue for the quarter was down 6.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Equities research analysts predict that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in PBH. UMB Bank n.a. boosted its stake in shares of Prestige Consumer Healthcare by 81.8% in the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock valued at $26,000 after purchasing an additional 144 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Prestige Consumer Healthcare by 312.5% in the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock valued at $26,000 after buying an additional 250 shares during the period. Maseco LLP bought a new position in Prestige Consumer Healthcare in the second quarter valued at approximately $27,000. Opal Wealth Advisors LLC acquired a new stake in Prestige Consumer Healthcare during the 1st quarter worth $38,000. Finally, Geneos Wealth Management Inc. grew its holdings in Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after acquiring an additional 269 shares during the period. 99.95% of the stock is currently owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.